Century Therapeutics shares are trading higher after the company announced it received FDA clearance of IND application for CNTY-101 in Systemic Lupus Erythematosus.
Portfolio Pulse from Benzinga Newsdesk
Century Therapeutics' stock is up following the FDA's clearance of their IND application for CNTY-101, aimed at treating Systemic Lupus Erythematosus.
December 06, 2023 | 5:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Century Therapeutics, trading under the ticker IPSC, saw its shares rise after announcing FDA clearance for its CNTY-101 IND application for Systemic Lupus Erythematosus.
The FDA clearance of an IND application is a significant regulatory milestone for biotech companies, often leading to positive investor sentiment and a potential increase in stock price. As this clearance is for a treatment in a therapeutic area with high unmet medical need, it is likely to be viewed positively by the market.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100